Rogel Clarissa Schmidt, Souza-Santana Fabiana Covolo de, Marcos Elaine Valim Camarinha, Ogawa Marilia Marufuji, Basso Geovana, Tomimori Jane
Medical school student, Universidade Federal de São Paulo, São Paulo (SP), Brazil.
Laboratory of Immunogenetics, Instituto Lauro de Souza Lima, Bauru (SP), Brazil.
An Bras Dermatol. 2019 Jul 29;94(3):287-292. doi: 10.1590/abd1806-4841.20197322.
Renal transplant recipients are submitted to immunosuppression to avoid graft rejection, which makes them susceptible to various conditions. Furthermore, these individuals present malignant tumors more frequently than the general population, including nonmelanoma skin cancer. The individual genetic basis that acts in the pathogenesis of cutaneous cancer may present a protection or susceptibility factor for disease development. One of these factors is the HLA complex.
To investigate HLA alleles association to the occurrence of nonmelanoma skin cancer in renal transplant recipients from São Paulo State.
A total of 213 patients (93 renal transplant recipients with nonmelanoma skin cancer and 120 renal transplant recipients without nonmelanoma skin cancer) were evaluated by retrospective and cross-sectional study. Epidemiological, clinical and HLA typing data were found in databases. HLA class I (A, B) and class II (DR) alleles were compared to establish their association with nonmelanoma skin cancer.
Comparing renal transplant recipients with and without nonmelanoma skin cancer, the HLA-B13 allele was associated with higher risk of developing nonmelanoma skin cancer while B45 and B*50 alleles were associated with protection.
The HLA A, B and DR alleles identification for the kidney transplantation routine is done by low and medium resolution techniques that do not allow discrimination of specific alleles.
The involvement of HLA alleles in nonmelanoma skin cancer in renal transplant recipients was confirmed in this study. Renal transplant recipients with HLA-B*13 showed higher risk for developing a skin cancer (OR= 7.29) and should be monitored for a long period of time after transplantation.
肾移植受者需接受免疫抑制治疗以避免移植排斥,这使他们易患各种疾病。此外,这些个体比普通人群更易患恶性肿瘤,包括非黑色素瘤皮肤癌。在皮肤癌发病机制中起作用的个体遗传基础可能是疾病发展的保护或易感因素。其中一个因素是HLA复合体。
研究圣保罗州肾移植受者中HLA等位基因与非黑色素瘤皮肤癌发生的相关性。
通过回顾性和横断面研究对总共213例患者(93例患有非黑色素瘤皮肤癌的肾移植受者和120例未患非黑色素瘤皮肤癌的肾移植受者)进行评估。在数据库中查找流行病学、临床和HLA分型数据。比较HLA I类(A、B)和II类(DR)等位基因,以确定它们与非黑色素瘤皮肤癌的相关性。
比较患有和未患非黑色素瘤皮肤癌的肾移植受者,HLA-B13等位基因与发生非黑色素瘤皮肤癌的较高风险相关,而B45和B*50等位基因与保护作用相关。
肾移植常规中HLA A、B和DR等位基因的鉴定是通过低分辨率和中分辨率技术进行的,这些技术无法区分特定等位基因。
本研究证实了HLA等位基因参与肾移植受者的非黑色素瘤皮肤癌发病过程。携带HLA-B*13的肾移植受者患皮肤癌的风险较高(OR = 7.29),移植后应长期监测。